HENATINIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H29FN4O4
Molecular Weight	468.5206
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(NC2=C1C(=O)N(C[C@H](O)CN3CCOCC3)CCC2)\C=C4/C(=O)NC5=C4C=C(F)C=C5

InChI

InChIKey=MCTXSDCWFQAGFS-UEXNTNOUSA-N

InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01416623 | https://www.ncbi.nlm.nih.gov/pubmed/23587531 | https://adisinsight.springer.com/drugs/800037384

Henatinib was developed as a multitargeted tyrosine kinase inhibitor with antitumor activities. Henatinib is an endothelial growth factor receptor type 2 (VEGFR2) antagonist. The drug participated in phase I clinical trial to evaluate the safety and tolerability in patients with advanced solid malignancies, however, the study was terminated. The current development status is unknown.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vascular endothelial growth factor receptor 2 112 Target ID: P35968 Gene ID: 3791.0 Gene Symbol: KDR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19662624	Antagonist 2849

PubMed

Title	Date	PubMed
Determination of henatinib in human plasma and urine by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application.	2013-06	23587531
Quantification of henatinib maleate, a novel potent inhibitor of VEGF receptors, in rat plasma by LC-MS/MS.	2010-04	19662624

Patents

Sample Use Guides

In Vivo Use Guide

Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily

Route of Administration: Oral

Name

Type

Language

HENATINIB

Common Name

English

PYRROLO(3,2-C)AZEPIN-4(1H)-ONE, 2-((Z)-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-5,6,7,8-TETRAHYDRO-5-((2R)-2-HYDROXY-3-(4-MORPHOLINYL)PROPYL)-3-METHYL-

Preferred Name

English

Code System Code Type Description

ChEMBL

CHEMBL3545416